| Drug Name |
Tasimelteon |
| Drug ID |
BADD_D02118 |
| Description |
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010. |
| Indications and Usage |
Tasimelteon is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). |
| Marketing Status |
approved; investigational |
| ATC Code |
N05CH03 |
| DrugBank ID |
DB09071
|
| KEGG ID |
D09388
|
| MeSH ID |
C478745
|
| PubChem ID |
10220503
|
| TTD Drug ID |
D0Q5MQ
|
| NDC Product Code |
76397-019; 66499-0054; 69766-039; 69238-2548; 76397-015; 43068-220; 43068-304; 67651-0307; 0480-4490 |
| UNII |
SHS4PU80D9
|
| Synonyms |
tasimelteon | N-((2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)propanamide | BMS 214778 | BMS214778 | BMS-214778 |
